Alembic Pharma receives USFDA final approval for Sacubitril-Valsartan tablets, equivalent to Novartis' Entresto, in heart failure treatment.
Alembic Pharma receives final approval from USFDA for Sacubitril and Valsartan Tablets, used in heart failure treatment. The tablets are therapeutically equivalent to Novartis' Entresto Tablets, with an estimated market size of US$5.3 billion. Alembic now has a total of 202 ANDA approvals (174 final approvals and 28 tentative approvals) from the USFDA.
May 30, 2024
4 Articles